



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 21 October 2025

INSIDE INFORMATION

In compliance with the reporting requirements provided for in article 226 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, "ROVI" or the "Company") hereby informs the National Securities Market Commission that ROVI will collaborate with F. Hoffmann-La Roche Ltd (hereinafter, "Roche") for the manufacture of a new medicine, currently in clinical development, from Roche's metabolic and cardiovascular portfolio. The parties intend to sign the final agreement in the coming days. Final execution will also be reported to the market.

Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Office
Laboratorios Farmacéuticos ROVI, S.A.

ROVI announces a collaboration with Roche for the manufacture of a new medicine in development

- The Swiss company has placed its confidence in ROVI for the manufacture of this product for its global launch.

Madrid, Spain –21 October 2025. Today, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical company specialising and engaging in the research, development, licensed manufacturing and marketing of small molecules and biological specialties, has announced that its subsidiary ROVI Pharma Industrial Services, S.A.U. (hereinafter, “ROIS”) will collaborate with F. Hoffmann-La Roche Ltd. (hereinafter, “Roche”) for the manufacture of a new medicine, currently in clinical development, from Roche’s metabolic and cardiovascular portfolio. The parties intend to sign the final agreement in the coming days. Final execution will also be reported to the market.

ROIS will place a high-speed filling line at its facility in San Sebastián de los Reyes (Madrid) at Roche’s disposal.

For 2030, ROVI estimates that the agreement will contribute to a minimum increase of between 20% and 25% in contract manufacturing business sales compared with the 2024 figure.

Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer, said: “We are delighted to become Roche’s strategic partner in the manufacture of this innovative product to be distributed globally and its potential to contribute to enhancing the quality of life of millions of people. Furthermore, we take special pride

in positioning Spain among the leaders in latest-generation pharmaceutical production. Over recent years, guided by our growth strategy, our company has made significant investments in increasing its capacities and incorporating innovative technology to make us one of the largest contract manufacturing companies (CDMO) of injectables in the world.”

Forward-looking statements

This press release contains forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or actual achievements of ROVI, or its industrial results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The information contained in this press release represents the expectations and beliefs of ROVI at the date hereof. ROVI wishes to state that future events or developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be considered to represent the expectations or beliefs of ROVI at any date subsequent to the date hereof.

About ROVI

ROVI is a pan-European pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules

and biological specialties. The company, in a continuous expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of over 40 products, among which its flagship product, bemiparin, now present in more than 60 countries all over the world, should be highlighted. Likewise, ROVI markets its enoxaparin biosimilar, developed in-house, in Europe and this product is now present in around 60 countries. ROVI is continuing to develop the ISM® technology platform, a cutting-edge line of research in the field of prolonged drug release, with proven advantages. For more information, please visit www.rovi.es

ROVI's contacts:

Media:

Beatriz García

+34 662 570 818

bgarciasuarez@rovi.es

Investors:

Marta Campos

mcampos@rovi.es

Beatriz de Zavala

bdezavala@rovi.es

Victoria López-Belmonte

vlopez-belmonte@rovi.es